TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32007230

Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin for 3 months, then Ticagrelor alone for 9 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clopidogrel + Aspirin for 3 months, then Clopidogrel alone for 9 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 40
Study: 33866968

Group type: EXPERIMENTAL
Intervention: Stay Strong App
Number of subjects: 156

Group type: COMPARATOR
Intervention: Hep B Story (contact control app)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Stay Strong App (for those with moderate to severe symptoms)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Hep B Story (for those with moderate to severe symptoms)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Dialysis attendance
Number of subjects: 156
Study: 33512799

Group type: EXPERIMENTAL
Intervention: Low-dose GLP-2 (1 pmol × kg × min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose GLP-2 (10 pmol × kg × min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study: 34245356

Group type: EXPERIMENTAL
Intervention: Colgate Max Expert White (CMEW)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Signal Daily White (SDW)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Himalaya Sparkly White Herbalis (HSWH)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Signal White System (SWS)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rembrandt Deeply White + Peroxide (RDWP)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Splat Extreme White (SEW)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Splat White Plus (SWP)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Kalodont Multi Repair (control)
Number of subjects: 161
Study: 32506363

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with idarucizumab reversal in dabigatran-treated patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mechanical reperfusion (MeR) in patients with large vessel occlusion
Number of subjects: 51
Study: 36086723

Group type: EXPERIMENTAL
Intervention: Lidocaine (2%) 1.5 mg/kg bolus before induction followed by 2 mg/kg/h continuous infusion up to skin closure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 60
Study: 32992184

Group type: EXPERIMENTAL
Intervention: Local vibration applied to the plantar region for 15 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (no vibration) applied to the plantar region for 15 min
Number of subjects: 30
Study: 36326756

Group type: EXPERIMENTAL
Intervention: 100 μg dose of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 500 μg dose of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 100 μg and 500 μg doses of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Highest vaccine dose (500 μg)
Number of subjects: 66
Study: 34292819

Group type: EXPERIMENTAL
Intervention: Running knotless barbed suture
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard monofilament suture
Number of subjects: 1000
Study: 32454356

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR), n = 124
Number of subjects: 247

Group type: COMPARATOR
Intervention: Resource and referral, n = 123
Number of subjects: 247
Study: 33616843

Group type: EXPERIMENTAL
Intervention: Aloe vera 3% ointment, 1 g twice daily for 6 weeks
Number of subjects: 20
Study: 33315181

Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PI
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 36
Study: 33710717

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35595530

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35630065

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 125
Study: 32055016

Group type: EXPERIMENTAL
Intervention: 24 GyE proton beam therapy (PBT) with intravitreal anti-VEGF therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham radiation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 24 GyE proton beam therapy (PBT)
Number of subjects: 30
Study: 35589614

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (meta-analysis)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 33756511

Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 36473929

Group type: EXPERIMENTAL
Intervention: Individualized + optimized nutrition (experimental group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Optimized nutrition alone (control)
Number of subjects: 91
Study: 33290142

Group type: EXPERIMENTAL
Intervention: Cureit supplementation
Number of subjects: 30
Study: 35534907

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (HBCR) with ICT guidance for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study: 33444649

Group type: EXPERIMENTAL
Intervention: Acute anorexia nervosa (AN)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Short-term weight restoration
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Long-term recovery from AN
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Physical activity in long-term recovered AN patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 178
Study: 32468989

Group type: EXPERIMENTAL
Intervention: EXTRAS
Number of subjects: 573

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study: 32171288

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg QD
Number of subjects: 209

Group type: COMPARATOR
Intervention: Sunitinib 50 mg QD in 6-week cycles (4 weeks on, 2 weeks off)
Number of subjects: 209
Study: 35934637

Group type: EXPERIMENTAL
Intervention: Sub-epidermal moisture scanning (SEMS) daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine pressure injury prevention care and daily visual skin assessment
Number of subjects: 100
Study: 32604072

Group type: EXPERIMENTAL
Intervention: Standard warm-up (S-WU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10-minute warm-up at 60% of maximum oxygen uptake (60%-WU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: No warm-up (No-WU)
Number of subjects: 15
Study: 35964100

Group type: EXPERIMENTAL
Intervention: Combined chest compression and abdominal compression-decompression CPR (CO-CPR)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (STD-CPR)
Number of subjects: 278
Study: 34420948

Group type: EXPERIMENTAL
Intervention: Compression stockings (CS) with an interface pressure of 23-32 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compression stockings (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No compression stockings (without CS)
Number of subjects: 0
Study: 35180125

Group type: EXPERIMENTAL
Intervention: Fosgonimeton 40 mg in AD subjects (n=7)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo in AD subjects (n=4)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses) in healthy young males (n=48)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses) in healthy elderly subjects (n=29)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 32190990

Group type: EXPERIMENTAL
Intervention: Bimonthly ranibizumab (0.5 mg intravitreal)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) ranibizumab (0.5 mg intravitreal)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Pro re nata (PRN) ranibizumab (0.5 mg intravitreal)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Bimonthly ranibizumab
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) ranibizumab
Number of subjects: 306
Study: 36307008

Group type: EXPERIMENTAL
Intervention: Bridge (person-centered collaborative care)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 120
Study: 34078520

Group type: EXPERIMENTAL
Intervention: Self-administered cryotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 90
Study: 32058560

Group type: EXPERIMENTAL
Intervention: Nonparametric multivariate analysis of variance with residual randomization in permutation procedures (RRPP)
Number of subjects: 0
Study: 35581042

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with erector spinae plane blocks (ESPB)
Number of subjects: 108

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 108
Study: 32554735

Group type: EXPERIMENTAL
Intervention: Non-absorbable sutures
Number of subjects: 192

Group type: COMPARATOR
Intervention: Absorbable sutures
Number of subjects: 192
Study: 35398399

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) for depression
Number of subjects: 26
Study: 34193264

Group type: EXPERIMENTAL
Intervention: Melissa officinalis syrup
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36039762

Group type: EXPERIMENTAL
Intervention: MEDI6012 (2- or 6-dose regimen)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: MEDI6012 (6 doses)
Number of subjects: 593
Study: 34753423

Group type: EXPERIMENTAL
Intervention: SCB with mepivacaine 1%, 25-30 ml (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SCB with ropivacaine 0.5%, 25-30 ml (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anaesthesia (GA) with propofol/fentanyl/sevoflurane (n=30)
Number of subjects: 90
Study: 32977180

Group type: EXPERIMENTAL
Intervention: Convolutional neural network and image saliency technique for cardiac MRI segmentation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Regional growth technique (control)
Number of subjects: 85
Study: 35675601

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated after skin incision
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated 0-30 minutes before skin incision
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated more than 30-60 minutes before skin incision
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin initiated more than 60 minutes before skin incision
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study: 33231285

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 35 cycles
Number of subjects: 262

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of carboplatin plus paclitaxel or pemetrexed Q3W with optional pemetrexed maintenance)
Number of subjects: 262
Study: 33403734

Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35854270

Group type: EXPERIMENTAL
Intervention: ReCoN intervention (Reducing Coercion in Norway)
Number of subjects: 0
Study: 33598874

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/31.25/25 μg, 100/62.5/25 μg, 200/31.25/25 μg, 200/62.5/25 μg)
Number of subjects: 1891

Group type: COMPARATOR
Intervention: FF/VI (100/25 μg, 200/25 μg)
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI and FF/VI
Number of subjects: 1891
Study: 32758049

Group type: EXPERIMENTAL
Intervention: PDT (MB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PDT (PA+MB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PDT (PA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PA+MB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LLL
Number of subjects: 120

Group type: COMPARATOR
Intervention: S (saline)
Number of subjects: 120
Study: 34649396

Group type: EXPERIMENTAL
Intervention: Social Intelligence Counseling Intervention (eight 1-hour weekly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 0
Study: 36130208

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer program
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Controlled direct effect (CDE) of random assignment
Number of subjects: 443
Study: 32060547

Group type: EXPERIMENTAL
Intervention: Tobacco prevention interventions (three types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarettes and smokeless tobacco
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-cigarettes, cigarillos/little cigars, and hookah
Number of subjects: 0
Study: 34512526

Group type: EXPERIMENTAL
Intervention: Aerobic physical fitness training for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation sessions for four weeks (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 and fibrinogen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hs-CRP levels at 3 months after stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF-alpha levels
Number of subjects: 0
Study: 35440458

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT) for perinatal loss
Number of subjects: 274

Group type: COMPARATOR
Intervention: Group coping with depression (Control)
Number of subjects: 274
Study: 34653648

Group type: EXPERIMENTAL
Intervention: Telepsychiatry group (at least 50% of treatments via telemedicine, with at least one face-to-face treatment within six months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face (FTF) group (all treatments conducted FTF, with no telemedicine)
Number of subjects: 0
Study: 36387337

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no pitavastatin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 positive subgroup)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 negative subgroup)
Number of subjects: 70
Study: 33814391

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Laser therapy with antioxidant medication
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 98
Study: 33529280

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study: 36113491

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34489297

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 0
Study: 32345170

Group type: EXPERIMENTAL
Intervention: Investigational treatment for RCC/UCC
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cough Severity Diary (CSD)
Number of subjects: 253
Study: 35723686

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (40 mg loading bolus followed by 40 mg/day for 7 days, then tapering over 20 days)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone
Number of subjects: 586
Study: 34423525

Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) 20g/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (sunflower oil) 20g/d
Number of subjects: 46
Study: 32100943

Group type: EXPERIMENTAL
Intervention: Nanogold-coated toothbrush
Number of subjects: 84

Group type: COMPARATOR
Intervention: Uncoated toothbrush
Number of subjects: 84
Study: 34260808

Group type: EXPERIMENTAL
Intervention: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts administered over a 12-week period
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 32770246

Group type: EXPERIMENTAL
Intervention: Nicotine Vaping Product (NVP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination Nicotine Replacement Therapy (NRT)
Number of subjects: 100
Study: 35312968

Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate 1% ophthalmic solution (0.5 mg and 1.0 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1.0 mg intravenous (IV) atropine dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate 1% ophthalmic solution
Number of subjects: 15
Study: 33098041

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-busulfan (CyBu)
Number of subjects: 70

Group type: COMPARATOR
Intervention: busulfan-cyclophosphamide (BuCy)
Number of subjects: 70
Study: 32485761

Group type: EXPERIMENTAL
Intervention: Monosyllables
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bisyllables
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trisyllables
Number of subjects: 18
Study: 35551840

Group type: EXPERIMENTAL
Intervention: Direct bonding of mandibular fixed retainers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Indirect bonding of mandibular fixed retainers
Number of subjects: 64
Study: 34140765

Group type: EXPERIMENTAL
Intervention: Pyrotinib (80 mg single dose on days 1 and 9) co-administered with Itraconazole (200 mg once-daily from days 6 to 22)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pyrotinib (80 mg single dose on days 1 and 9)
Number of subjects: 18
Study: 32810739

Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg, 1 hour pre-exercise, chronic supplementation for 21 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (1 hour pre-exercise, chronic supplementation for 21 days)
Number of subjects: 24
Study: 33859520

Group type: EXPERIMENTAL
Intervention: Oral resveratrol (480 mg per day for 4 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 32289294

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML)
Number of subjects: 42
Study: 35284956

Group type: EXPERIMENTAL
Intervention: HybridAPC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sharp excision
Number of subjects: 39
Study: 34181475

Group type: EXPERIMENTAL
Intervention: XAV-19 at 0.5 mg/kg at day 1 and day 5 (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: XAV-19 at 2 mg/kg at day 1 and day 5 (group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: XAV-19 at 2 mg/kg at day 1 (group 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 33153527

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy–Emotion Development (PCIT-ED)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 118
Study: 34348668

Group type: EXPERIMENTAL
Intervention: Lidocaine plus dexmedetomidine (group LD)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (group D)
Number of subjects: 248
Study: 35512155

Group type: COMPARATOR
Intervention: Standard dosing: 1 g of IV TXA 30 min before skin incision, and 1 g at postoperative 30 min and 3 h.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Weight-based dosing: 10 mg/kg IV TXA 30 min before skin incision, and 10 mg/kg at postoperative 30 min and 3 h.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups (standard and weight-based dosing of IV TXA).
Number of subjects: 99
Study: 35758436

Group type: EXPERIMENTAL
Intervention: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated about a month after stroke
Number of subjects: 82

Group type: COMPARATOR
Intervention: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated more than 6 months after stroke (late therapy)
Number of subjects: 82
Study: 33534439

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) denervation combined with bupivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bupivacaine alone (control group)
Number of subjects: 76
Study: 32207359

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 33497028

Group type: EXPERIMENTAL
Intervention: nCPAP+oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 60
Study: 35945705

Group type: EXPERIMENTAL
Intervention: Multi-session brief intervention (MBI)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Single-session brief intervention (SBI)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 362
Study: 34039473

Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) for margin accentuation during pancreaticoduodenectomy (PD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non-IRE (control group)
Number of subjects: 111
Study: 32159859

Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment system + ProTaper Gold (PTG) instrumentation system up to PTG F2
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reciproc Blue system up to the instrument RB25
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reciproc system up to the instrument R25
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Wave One Gold (WOG) system up to the instrument WOG25
Number of subjects: 65